Bluejay Diagnostics, Inc. (BJDX)
NASDAQ: BJDX · Real-Time Price · USD
3.840
-0.060 (-1.54%)
Dec 20, 2024, 4:00 PM EST - Market closed
Bluejay Diagnostics Employees
Bluejay Diagnostics had 10 employees as of December 31, 2023. The number of employees decreased by 6 or -37.50% compared to the previous year.
Employees
10
Change (1Y)
-6
Growth (1Y)
-37.50%
Revenue / Employee
n/a
Profits / Employee
-$858,855
Market Cap
2.06M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10 | -6 | -37.50% |
Dec 31, 2022 | 16 | 7 | 77.78% |
Dec 31, 2021 | 9 | - | - |
Related Stocks
Company Name | Employees |
---|---|
cbdMD | 52 |
Aptevo Therapeutics | 40 |
Cyclacel Pharmaceuticals | 12 |
TransCode Therapeutics | 10 |
Shuttle Pharmaceuticals Holdings | 8 |
Dermata Therapeutics | 8 |
IMAC Holdings | 4 |
Salarius Pharmaceuticals | 2 |
BJDX News
- 5 weeks ago - Bluejay Diagnostics Announces Reverse Stock Split - GlobeNewsWire
- 6 months ago - Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering - GlobeNewsWire
- 6 months ago - SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study) - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - GlobeNewsWire